SutroVax

Developing best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent deadly infectious diseases

SutroVax is a vaccine platform and development company whose mission is to deliver best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent deadly infectious diseases. The company is leveraging an exclusive license to Sutro Biopharma’s Xpress cell-free protein synthesis platform to develop vaccines with heightened immunity and broader protection than can be attained with existing platforms. SutroVax’s lead program is a potentially best-in-class pneumococcal conjugate vaccine (PCV) to prevent invasive pneumococcal disease.

Year of Investment

2017

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Foster City, California